Skip to content

Alefacept (Amevive)–This is the first biologic drug approved specifically to treat moderate to severe plaque psoriasis

Amevive, developed by Biogen, is the first biologic medicine approved to treat psoriasis. Amevive was specifically designed to target the underlying cause of psoriasis – an immune system dysfunction that drives skin cells to multiply uncontrollably. Alefacept is the first biological agent approved by the US Food and Drug Administration (FDA) for the treatment of moderate to severe chronic plaque psoriasis. Corticosteroid injections for severe pain and inflammation at specific joints are standard therapy. In 2003, Biogen’s alefacept (Amevive), a T cell targeted therapy, became the first biologic drug approved for treatment of psoriasis.

Alefacept (Amevive)--This is the first biologic drug approved specifically to treat moderate to severe plaque psoriasis 2It is marketed for the treatment of patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. This drug uses its cell-bridging ability to selectively induce death of specifically activated lymphocytes called CD4+ and CD8+. About 1.5 million Americans have moderate to severe psoriasis, and an estimated one million Americans have psoriatic arthritis. Amevive (alefacept) became the first biologic drug approved for psoriasis, while Genentech’s Raptiva (efalizumab) was approved for psoriasis last fall. Etanercept targets a specific protein that produces an inflammatory response in both psoriasis and psoriatic arthritis, said Craig Leonardi, M. Having an established record in treating psoriatic arthritis, etanercept is now the first of the new biologic drugs able to treat the full spectrum of psoriatic disease. Alefacept (Amevive) was the first biologic approved specifically for psoriasis treatment by the Food and Drug Administration, in early 2003. The biologics approved for treating chronic, moderate to severe plaque psoriasis now include alefacept, etanercept, and efalizumab (Raptiva).

Psoriasis is a skin condition that causes red, scaly patches called plaques. Medication options include topical therapy, which is applied to the skin, and systemic therapy, which is given by mouth or by injection. Systemic therapy, which is used for moderate to severe cases of psoriasis, includes oral medications (acitretin, cyclosporine, and methotrexate) and a new class of medications called biologics. As of November 16, 2011, alefacept (Amevive) is no longer available in the U.S. market. (South San Francisco, CA), gained Food and Drug Administration (FDA) approval in October 2003 for the treatment of moderate-to-severe psoriasis in people at least 18 years old. Alefacept (Amevive) This is the first biologic drug approved specifically to treat moderate to severe plaque psoriasis. It is administered by a doctor, who injects the drug once a week for 12 weeks.

Alefacept (amevive) Im Administration

Other Names: Alefacept. Maker: Biogen Inc. Mechanism of Action: AMEVIVE binds specifically to the CD2 molecule and prevents it from binding to LFA-3. And Europe for marketing approval of AMEVIVE for treating patients with moderate-to-severe chronic plaque psoriasis. AMEVIVE is the first biological treatment approved for psoriasis. Alefacept (Amevive) was the first biologic approved specifically for psoriasis treatment by the Food and Drug Administration, in early 2003. The biologics approved for treating chronic, moderate to severe plaque psoriasis now include alefacept, etanercept, and efalizumab (Raptiva). Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. (biologic) approved in the U.S. for the treatment of moderate to severe psoriasis. Drugs that can trigger the disease or cause a flare-up of symptoms include:. Biologics and small-molecule drugs being developed to treat psoriasis are showing encouraging results, but high costs could limit their use. Ustekinumab (Stelara; Centocor/Janssen), a monoclonal antibody that targets a subunit of IL-12, was approved to treat moderate and severe psoriasis in 2009. First received: December 4, 2006. Alefacept is a new anti-psoriatic drug within the group of the so-called biologics. There is a new generation of antipsoriatic drugs that specifically target T-cell mediated inflammatory pathways and that are approved for the treatment of moderate to severe psoriasis in the United States. Sadly, there is still no cure for psoriasis, but don’t be discouraged: There are many different treatments, both topical and systemic, that can clear it for periods of time. It was FDA-approved for psoriasis in 1997, with the proviso that it not be used for more than a year at a time. Alefacept (trade name Amevive): One of the first biologic drugs approved by the FDA specifically to treat moderate to severe plaque psoriasis this drug works by reducing the number of immune-activated T-cells in the skin, thus significantly reducing the major cause of psoriasis.

Psoriasis Treatment News: Biologics

The FDA looks set to license the first biotech drug for treatment of moderate to severe psoriasis later this year, after its dermatological and ophthalmic advisory panel’s recommended approval of Biogen’s (Cambridge, MA) Amevive (alefacept) in May. This is good news not only for Biogen, which sorely needs another drug on the market, but also for patients: the committee’s strong 8-2 majority for approval means that not just Biogen’s Amevive but at least three other biologicals could be available to severe psoriasis patients in the next two years. Increased levels of TNF are also found in psoriasis plaques. Topical treatments – usually used for mild to moderate psoriasis treatment. Biologics have recently emerged as a new treatment for patients with severe psoriasis symptoms. Individual anti-TNF drugs are not identical in their actions and often one is superior to the other in a particular disease. The target-specific mediators of inflammation have become an important and useful part of the dermatologists’ treatment armamentarium. 43 Multiple placebo-controlled Phase III clinical studies have assessed the safety and efficacy of efalizumab therapy in patients with moderate to severe chronic plaque psoriasis.